Extremely happy that our work got accepted in #ATVB! We functionally profiled 400 biobank samples, linking cellular lipid uptake, storage and handling to treatment outcomes of statin therapy and residual cardiovascular risk.
https://t.co/juNgqzoaVP
At MONCYTE Health we are looking for a laboratory technician. Are you ready to join a vibrant and exciting team, pushing boundaries in precision medicine? Please apply!
More information can be found here:
https://t.co/IKMwHKZWJZ
The closing date for applications is: 30.11.2025
Honoured to have participated in the inaugural @WHXTech in Dubai. Thank you to the organizers and speakers for a well-curated programme that fostered collaboration and focused discussions at the intersection of health and AI. Meaningful connections and an exceptional city!
Wonderful to present our data at @escardio at one of the most important cardiology conferences in Madrid 🇪🇸 — over 33k+ participants from 150 countries! Grateful for our team’s contribution and inspiring connections. @society_eas#MoncyteHealth
It was great to present our latest data at the #ESC Congress in #Madrid and to catch up with colleagues and friends at one of the most important cardiology conferences! Huge event with great science and clinical data + Madrid is nice! @society_eas
Join us at @escardio Congress in Madrid on 30 August, 13:15-14:00! Find out how alterations in cellular lipid metabolism link to outcomes of statin treatment & residual #cardiovascular risk - a step toward personalized cardiovascular care.
#ESC2025#highcholesterol
It was very nice to record this podcast. Talking about our research at @helsinkiuni and forming the spin-out company https://t.co/ZeMLCOGrYi!
@TamaraAlagirova@helsinkiuni
Dr @SimonPfisterer, Group Leader at the University of Helsinki and Chief Scientific Officer of Moncyte Ltd., was our guest in the latest episode of AtheroTalk. His work bridges cutting-edge research and clinical applications in dyslipidaemia and cardiovascular disease. We talk about his academic journey, his move into biotech, and his vision for the future of precision medicine in atherosclerosis.
🎧 Spotify: https://t.co/gQmEm80R43
🎧 Apple Podcasts: https://t.co/sMUVKvJCvx
🎧 Youtube: https://t.co/uIXm9VddV0 @ProfKausikRay@KatiOorni
It was great to record an #AtheroTalk podcast and talk about our research and establishing the startup company https://t.co/ZeMLCOGrYi! A big thank you to the team, especially Sanne M. and @azinkh96 for interviewing me and doing the recording. It has been a very nice experience!
Extremely happy that our work got accepted in #ATVB! We functionally profiled 400 biobank samples, linking cellular lipid uptake, storage and handling to treatment outcomes of statin therapy and residual cardiovascular risk.
https://t.co/juNgqzoaVP
The technology will be developed further by https://t.co/ZeMLCOGrYi to bring the first actionable diagnostic solution to dyslipidemia and cardiovascular disease, optimizing treatment selection and residual risk assessment.
@TamaraAlagirova@helsinkiuni
It has been a great pleasure to write this summary about new developments regarding LDL structure, function and cellular uptake, together with Gilles Lambert!
@CaixaResearch@helsinkiuni@HiLIFE_helsinki#PerMedFH https://t.co/aTVjMK5STi
We wrote an editorial discussing the importance of the conformation of apoB. ApoB-100: The guardian of LDL stability - Atherosclerosis https://t.co/vJIi06k6ig
This editorial was insipired by an article published earlier in @ATHjournal
https://t.co/DGW9UWC1XO
Exciting news 🚀 MONCYTE Health joins EUR 7 million Horizon Europe funded international consortium for earlier diagnosis and management of Familial Hypercholesterolemia (FH)🔥
Full Press Release here: https://t.co/hFKN6FeWmR
My followers dropped by 25% during the past 6 weeks. ➕ Content on this platform is getting increasingly difficult to enjoy. Checking out new options: https://t.co/cGUH82Wml4
Out now! We established a platform for functional characterization of gene variants, providing insight for 315 LDLR variants. Functional data improves cardiovascular risk assessment, going beyond "pathogenic" and "benign" groups. Important for #FH
https://t.co/RORf5cQvqI